image credit: Unsplash

Gene therapy player InnoSkel debuts with €20M for rare skeletal diseases

December 14, 2020

Elvire Gouze Ph.D., a serial entrepreneur and expert in skeletal disorders, has formed another company—InnoSkel—after agreeing to sell her first venture Therachon to Pfizer for $340 million upfront last year.

Like Therachon, InnoSkel is focusing on diseases that result in dwarfism, but using a different approach. Therachon’s lead drug TA-46 was a soluble FGFR3 receptor designed to interrupt a molecule pathway linked to dwarfism, but InnoSkel will focus on gene therapies that will target underlying defects as a one-shot therapy.

Read More on FierceBiotech